 |
|
Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations
E. Patchen Dellinger, MD;
Timothy J. Babineau, MD;
Paul Bleicher, MD, PhD;
Allen B. Kaiser, MD;
G. Burton Seibert, PhD;
Russell G. Postier, MD;
Stephen B. Vogel, MD, PhD;
James Norman, MD;
David Kaufman, MD;
Susan Galandiuk, MD;
Robert E. Condon, MD;
for the Betafectin Gastrointestinal Study Group
Arch Surg. 1999;134:977-983.
Background Postoperative infections remain common after high-risk gastrointestinal procedures. PGG-glucan (Betafectin; Alpha Beta Technology Inc, Worcester, Mass), derived from yeast cell walls, promotes phagocytosis and intracellular killing of bacterial pathogens by leukocytes, prevents infection in an animal model of wound infection, and acts synergistically with antibiotics to reduce mortality in rat peritonitis.
Hypothesis We hypothesized that infectious complications in these patients might be reduced by the administration of a nonspecific immune-enhancing agent.
Design Multicenter, prospective, randomized, double-blind, placebo-controlled trial of 1249 patients prospectively stratified into colorectal or noncolorectal strata.
Setting Thirty-nine medical centers throughout the United States.
Patients Aged 18 years or older, scheduled for gastrointestinal procedure lasting 2 to 8 hours, with 2 or more defined risk factors.
Interventions PGG-glucan, 0.5 mg/kg or 1.0 mg/kg, or placebo once preoperatively and 3 times postoperatively. All patients received standardized antibiotic prophylaxis.
Main Outcome Measures Serious infection or death within 30 days.
Results All randomized patients revealed no difference in serious infections and deaths in the treated groups compared with placebo groups (15% vs 14%, P>.90). In the prospectively defined noncolorectal stratum (n=391), PGG-glucan administration was associated with a statistically significant relative reduction (39%) in serious infections and death (placebo, 46 [36%] of 129 vs either PGG-glucan group, 29 [21%] of 132 and 28 [22%] of 130, P<.02). PGG-glucan reduced postoperative infection or death in malnourished patients having noncolorectal procedures (31 [44%] of 70, placebo group; 16 [24%] of 68, 0.5-mg/kg PGG-glucan group; 12 [17%] of 72, 1.0-mg/kg PGG-glucan group; P<.001). Study drug was stopped owing to adverse effects more frequently for patients receiving PGG-glucan than placebo (2%, 4%, and 7% for the placebo group, 0.5-mg/kg PGG-glucan group, and 1.0-mg/kg PGG-glucan group, respectively, P<.003).
Conclusion Perioperative administration of PGG-glucan reduced serious postoperative infections or death by 39% after high-risk noncolorectal operations.
From the Department of Surgery, University of Washington School of Medicine, Seattle, (Dr Dellinger); Beth Israel Deaconess Medical Center, Boston, Mass (Dr Babineau); Alpha-Beta Technology, Worcester, Mass (Dr Bleicher); the Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn (Dr Kaiser); StatNet Statistical Services Network, Haverhill, Mass (Dr Seibert); University of Oklahoma Health Sciences Center, Oklahoma City (Dr Postier); University of Florida College of Medicine, Gainesville (Dr Vogel); University of South Florida, Tampa (Dr Norman); Rochester General Hospital, Rochester, NY (Dr Kaufman); University of Louisville School of Medicine, Louisville, Ky (Dr Galandiuk); and the Medical College of Wisconsin, Milwaukee (Dr Condon). Dr Bleicher is currently at Phase Forward Inc, Newton, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The effect of PGG-{beta}-glucan on neutrophil chemotaxis in vivo
LeBlanc et al.
J. Leukoc. Biol. 2006;79:667-675.
ABSTRACT
| FULL TEXT
Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biologic Function
Tzianabos
Clin. Microbiol. Rev. 2000;13:523-533.
ABSTRACT
| FULL TEXT
|
